Paul G. Ambrose, Pharm.D., FIDSA
Institute for Clinical Pharmacodynamics
Paul G. Ambrose, Pharm.D., FIDSA, has worked in the anti-infective drug development area for 25 years, at large and small pharmaceutical companies, and small research institutes. During this time, he has been involved with analyses and data generation for over 100 agents, spanning from small molecule (antibiotics and antifungals) to large molecule (monoclonal antibodies) antimicrobial agents.
Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained through the use of non-clinical (in vitro and animal) PK-PD infection models has been leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities.
He has been at the forefront of using this approach for identifying effective anti-infective dosing regimens, regulatory decision-making and as support for FDA, EUCAST, CLSI and USCAST susceptibility breakpoint determinations.
Ambrose has authored or co-authored over 150 peer-reviewed scientific publications and approximately 300 scientific abstracts and has served as an editor for four textbooks, most notably the 1st and 2nd Editions of Antimicrobial Pharmacodynamics in Theory and Clinical Practice and served as editor of Antimicrobial Agents and Chemotherapy (AAC) and Diagnostic °®¶¹´«Ã½ and Infectious Disease (DMID).
Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained through the use of non-clinical (in vitro and animal) PK-PD infection models has been leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities.
He has been at the forefront of using this approach for identifying effective anti-infective dosing regimens, regulatory decision-making and as support for FDA, EUCAST, CLSI and USCAST susceptibility breakpoint determinations.
Ambrose has authored or co-authored over 150 peer-reviewed scientific publications and approximately 300 scientific abstracts and has served as an editor for four textbooks, most notably the 1st and 2nd Editions of Antimicrobial Pharmacodynamics in Theory and Clinical Practice and served as editor of Antimicrobial Agents and Chemotherapy (AAC) and Diagnostic °®¶¹´«Ã½ and Infectious Disease (DMID).